On May 17, Almazov Centre held a webinar of International Chronic Myeloid Leukemia Foundation for doctors and patients with chronic myeloid leukemia.
Head of Research Group, Researcher at the Basic Oncology Department of Genetic Engineering and Cell Therapy Group, Alexey Petukhov spoke about the biological safety of RNA and viral vector COVID-19 vaccines.
Head of Clinical Pharmacology Department Ksenia Zagorodnikova highlighted the clinical safety and efficacy of COVID-19 vaccines and explained why vaccination is necessary.
Although the need for vaccination is clear, certain concerns are raised about the need for vaccination by people with various conditions. This is particularly true for patients with severe diseases such as chronic myeloid leukemia. Tamara Chitanava, Junior Researcher at the Research Laboratory of Oncohematology, spoke about whether patients with this diagnosis are ready for vaccination (based on the results of a survey in social networks).
Elza Lomaia, Head of Research Institute of Immuno-Oncology and Cell Therapy of the WCRC for Personalized Medicine, ended the webinar with the presentation “COVID-19 vaccines and chronic myeloid leukemia: Recommendations.”
The participants of the webinar had an opportunity to ask questions and get qualified answers from experts.